Heparan sulfate proteoglycan expression in human lung‐cancer cells

Heparan sulfate (HS) functions as a co‐factor in several signal‐transduction systems that affect cellular growth, differentiation, adhesion and motility. HS, therefore, may also play a role in the malignant transformation of cells, tumor growth, cell invasiveness and the formation of tumor metastases. To explore this hypothesis, we analyzed the expression of HS and heparan sulfate proteoglycan (HSPG) in histological sections of human lung‐cancer tissues and assayed for the presence of HSPGs in extracts of human lung‐cancer cell lines, using a panel of native HS‐, Δ‐HS‐ and HSPG (syndecan, glypican, CD44 and perlecan) core protein–specific monoclonal antibodies. Compared to normal epithelia, non‐small‐cell lung carcinomas, particularly poorly differentiated tumors, often expressed reduced amounts of the major cell surface–associated HSPGs (most consistently of syndecan‐1). CD44 or CD44‐variant proteins, in contrast, were found on all tumor cells, irrespective of their differentiation. Perlecan, a matrix‐associated HSPG found in the basement membrane of normal bronchial epithelium, was consistently undetectable in invasive bronchogenic carcinomas. Staining reactions for native HS were consistently reduced in squamous‐cell lung carcinomas, in the cells in contact with the stroma and in the less differentiated areas of these tumors. Reactions for Δ‐HS, however, were not reduced, suggesting a structural change in the HS of these tumor cells. Poorly differentiated adenocarcinomas, in contrast, yielded strong HS and Δ‐HS reactions. Marked differences in HSPG expression also were observed among various non‐small‐cell lung carcinoma cell lines. Our results suggest that poorly differentiated lung tumors have markedly altered patterns of HSPG expression, which may contribute to their invasive phenotype. Int. J. Cancer 74:335–345, 1997. © 1997 Wiley‐Liss, Inc.

[1]  B. Klein,et al.  A plasmocyte selective monoclonal antibody (B‐B4) recognizes syndecan‐1 , 1996, British journal of haematology.

[2]  D. Schlessinger,et al.  Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome , 1996, Nature Genetics.

[3]  M. Jalkanen,et al.  The role of syndecan-1 in malignancies. , 1996, Annals of medicine.

[4]  V. Dixit,et al.  Elevated levels of syndecan-1 expression confer potent serum-dependent growth in human 293T cells. , 1995, Cancer research.

[5]  Masato Kato,et al.  Loss of cell surface syndecan-1 causes epithelia to transform into anchorage-independent mesenchyme-like cells. , 1995, Molecular biology of the cell.

[6]  J. Bell,et al.  Proteoglycan forms of the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon , 1995, The Journal of cell biology.

[7]  A. Yayon,et al.  Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis , 1994, Cell.

[8]  R. Iozzo,et al.  Abnormal expression of perlecan proteoglycan in metastatic melanomas. , 1994, Cancer research.

[9]  R. Iozzo,et al.  The biology of perlecan: the multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices. , 1994, The Biochemical journal.

[10]  R. Sanderson,et al.  Expression of syndecan-1 inhibits cell invasion into type I collagen. , 1994, The Journal of biological chemistry.

[11]  M. Mareel,et al.  Enlarged cell-associated proteoglycans abolish E-cadherin functionality in invasive tumor cells. , 1994, Cancer research.

[12]  A. Rapraeger The coordinated regulation of heparan sulfate, syndecans and cell behavior. , 1993, Current opinion in cell biology.

[13]  G. David Integral membrane heparan sulfate proteoglycans , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  N. Hynes,et al.  Translational suppression of syndecan-1 expression in Ha-ras transformed mouse mammary epithelial cells. , 1993, Molecular biology of the cell.

[15]  J Heino,et al.  Integrin-type extracellular matrix receptors in cancer and inflammation. , 1993, Annals of medicine.

[16]  X. Bai,et al.  Developmental changes in heparan sulfate expression: in situ detection with mAbs , 1992, The Journal of cell biology.

[17]  M. Jalkanen,et al.  Syndecan expression regulates cell morphology and growth of mouse mammary epithelial tumor cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[18]  W. Birchmeier,et al.  E-cadherin expression in squamous cell carcinomas of head and neck: inverse correlation with tumor dedifferentiation and lymph node metastasis. , 1991, Cancer research.

[19]  P. Herrlich,et al.  CD44 splice variants confer metastatic behavior in rats: homologous sequences are expressed in human tumor cell lines. , 1991, Cancer research.

[20]  G. Cherqui,et al.  Altered expression of proteoglycans in E1A-immortalized rat fetal intestinal epithelial cells in culture. , 1990, Cancer research.

[21]  W. Birchmeier,et al.  Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion , 1989, The Journal of cell biology.

[22]  P. Mora,et al.  Cells selected for high tumorigenicity or transformed by simian virus 40 synthesize heparan sulfate with reduced degree of sulfation. , 1981, The Journal of biological chemistry.

[23]  L. Liotta,et al.  Molecular mediators of interactions with extracellular matrix components in metastasis and angiogenesis. , 1994, Current opinion in oncology.

[24]  J. Spring,et al.  Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. , 1992, Annual review of cell biology.

[25]  I. Cohen,et al.  Heparan sulfate degradation in tumor cell invasion and angiogenesis. , 1988, Advances in experimental medicine and biology.